LONDON, Oct 22 (Reuters) - GlaxoSmithKline expectsto have the first doses of its Ebola vaccine ready late thisyear and is looking to work with the rest of the pharmaceuticalindustry to scale up production.
"I fully anticipate that the initial supply should beavailable before the year end," Chief Executive Andrew Wittytold reporters on Wednesday after reporting quarterly results.
"It will give WHO (World Health Organization) and otheragencies a useful tool," he said, adding that the GSK productwas likely to be the first vaccine to be deployed.
Johnson & Johnson, which is also developing an Ebolavaccine, said earlier that drugmakers were exploring ways to work together to make millions of vaccine doses available in2015.
GSK said such collaboration was essential to removepotential bottlenecks in the production and supply process."This situation requires new ways of working and thinking," hesaid. (Reporting by Ben Hirschler and editing by Kate Kelland)